Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zaleplon
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zaleplon is a nonbenzodiazepine hypnotic of the pyrazolopyrimidine class, primarily indicated for the short-term treatment of insomnia. It acts as a sedative by selectively binding to benzodiazepine sites on the alpha-1 subunit of the GABA-A receptor complex in the central nervous system, enhancing GABAergic inhibition and promoting sleep onset. Unlike traditional benzodiazepines, zaleplon has minimal effects on sleep architecture and is considered an ultrashort-acting agent. It was developed by King Pharmaceuticals[5][3][6].
- Brand names
- Sonata
02
Targets
GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)GABRA3 (Gamma-aminobutyric acid receptor subunit alpha-3)
Beyond the preview
Go deeper on zaleplon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zaleplon.